NCT03853109: AMG 404 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated or symptomatic brain metastases & leptomeningeal disease- see trial for details; Patients who have received prior anti-PD-1, -PD-L1/2, or -CTLA-4 therapy

Comments are closed.

Up ↑